Adverse behavioral effects in individuals with mental retardation and mood disorders treated with carbamazepine.
The incidence of carbamazepine-associated behavioral side effects in 65 individuals with mental retardation and additional seizure and/or psychiatric or behavioral disorders was evaluated. We identified 6 patients (9.2%) who experienced medication side effects, ranging from irritability to mania. Four of the 20 patients (20%) who received carbamazepine purely for treatment of a behavioral or psychiatric disorder experienced medication side effects, whereas none of the 21 patients treated for an isolated seizure disorder experienced similar effects. This difference was statistically significant, p less than .05. The incidence of behavioral side effects of medication was not associated with age, sex, or serum carbamazepine level. The chemical structure and mechanism of carbamazepine use in various disease processes were discussed.
Friedman
D L
DL
Developmental Disabilities Center, Morristown Memorial Hospital, NJ 07962-1956.
Kastner
T
T
Plummer
A T
AT
Ruiz
M Q
MQ
Henning
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use; D012920:Social Behavior Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology
D011619:Psychotropic Drugs; D002220:Carbamazepine